Last updated on July 2019

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Brief description of study

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

Clinical Study Identifier: NCT02963766

Find a site near you

Start Over

University of Arizona

Tucson, AZ United States
  Connect »

Touro University

Vallejo, CA United States
  Connect »

Indiana University Hospital

Indianapolis, IN United States
  Connect »

Children's Mercy Hospital

Kansas City, MO United States
  Connect »

ECU Pediatric Specialty Care

Greenville, NC United States
  Connect »

Multicare Health System

Tacoma, WA United States
  Connect »

CAMC Institute

Charleston, WV United States
  Connect »

Advanced Research Center

Anaheim, CA United States
  Connect »

JC Cabaccan

San Jose, CA United States
  Connect »

Schwerpunktpraxis Diabetes

Saint Ingbert-Oberwürzbach, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.